アミロイド阻害剤の分子基礎を定義する:ヒト島のアミロイドポリペプチド-インスリン相互作用
Anna C Susa1, Chun Wu, Summer L Bernstein
1Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States.
Journal of the American Chemical Society
|August 22, 2014
まとめ
インスリンとそのB鎖は,そのコンパクトな形を安定させ,2型糖尿病に関連するアミロイド線維の形成を抑制することによって,ヒト島アミロイドポリペプチド (hIAPP) の集積を防止します.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 糖尿病に関する研究
背景:
- ヒューマン・アイレット・アミロイド・ポリペプチド (hIAPP) は,アミリンとも呼ばれ,臓の小島からインスリンと共に分泌されるホルモンです.
- hIAPPの集積は,2型糖尿病の進行と小島細胞移植不全に関与しています.
- インスリンがhIAPPのアミロイド形成を阻害するメカニズムは,まだ十分に理解されていないため,合理的な薬剤設計を妨げています.
研究 の 目的:
- hIAPPのアミロイド線維細胞形成におけるインスリンとその成分の抑制メカニズムを解明する.
- インスリンとその鎖がhIAPPのモノマーとどのように相互作用するかを理解する.
主な方法:
- イオン流動性スペクトロメトリーに基づく質量スペクトロメトリーは,集積を特徴付けるために使用されました.
- 繊維の形成を視覚化するために,原子力顕微鏡を用いた.
- 実験的発見をサポートするために,全原子分子モデリングが利用されました.
主要な成果:
- インスリンとインスリンB鎖は,hIAPP線維細胞形成の強力な阻害剤として特定されました.
- これらの阻害剤は,hIAPPモノメアのコンパクト同型を標的とする.
- 均衡は,集積傾向のあるhIAPPの拡張同型から遠ざけられた.
結論:
- インスリンとそのB鎖は,コンパクトなモノマー構成を安定させることで,hIAPPのアミロイドゲネシスを阻害する.
- この安定化は,βシート構造への移行と,その後の繊維の形成を防ぐ.
- この発見は,II型糖尿病の研究に係るインスリンの抗アミロイド原性に関する洞察を提供している.
関連する概念動画
Insulin: Biosynthesis, Chemistry, and Preparation
2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
Insulin: The Receptor and Signaling Pathways
5.9K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.9K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Production of Pharmaceuticals
90
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
90
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K


